Kawase Hiroshi, Ebihara Yuma, Shichinohe Toshiaki, Nakamura Fumitaka, Murakawa Katsuhiko, Morita Takayuki, Okushiba Shunichi, Hirano Satoshi
Department of Surgery, Sapporo Kiyota Hospital, Shinei 1-1-1-1, Kiyota-ku, Sapporo, Hokkaido, Japan.
Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, North-15, West-7, Kita-ku, Sapporo, Hokkaido, Japan.
Langenbecks Arch Surg. 2017 Feb;402(1):41-47. doi: 10.1007/s00423-017-1559-8. Epub 2017 Jan 29.
Despite its spread and advances, laparoscopic gastrectomy (LG) for advanced gastric cancer (AGC) remains controversial. The aim of this study was to evaluate the oncologic outcomes and to identify the potential risk factors for recurrence and survival after LG in AGC patients.
The medical records of patients who underwent radical LG for histopathologically diagnosed stage IB or more advanced gastric cancer from 2004 to 2012 were collected. The clinicopathologic factors and outcomes were evaluated retrospectively.
LG was performed for 300 patients, with a median operative time of 278 min and blood loss of 46 ml. Postoperative morbidity was defined as Clavien-Dindo grades III and IV and occurred in 13 patients (6.3%) in the laparoscopic distal gastrectomy group. The pathologic stage was IB in 109 patients (36.3%), IIA in 77 patients (25.7%), IIB in 48 patients (16.0%), IIIA in 31 patients (10.3%), IIIB in 19 patients (6.3%), and IIIC in 16 patients (5.3%). Median follow-up period was 55.2 months. The 3-year relapse-free survival (RFS) rate was 92.7% for stage IB, 87.0% for IIA, 68.8% for IIB, 64.5% for IIIA, 47.4% for IIIB, and 43.8% for IIIC. The 5-year actual overall survival rate was 91.1% for stage IB, 72.7% for II, and 62.5% for III. Multivariate analysis revealed postoperative complication as an independent risk factor for RFS.
LG for AGC was feasible and provided comparable oncologic outcomes with those previously reported. Postoperative complications correlated with poor prognosis. Randomized control trials should be conducted to confirm these results of LG for AGC in the general population.
尽管腹腔镜胃切除术(LG)已广泛开展且技术不断进步,但针对进展期胃癌(AGC)的腹腔镜胃切除术仍存在争议。本研究旨在评估肿瘤学结局,并确定AGC患者接受LG术后复发和生存的潜在风险因素。
收集2004年至2012年间因组织病理学诊断为IB期或更晚期胃癌而接受根治性LG的患者的病历。对临床病理因素和结局进行回顾性评估。
300例患者接受了LG,中位手术时间为278分钟,失血量为46毫升。术后并发症定义为Clavien-DindoⅢ级和Ⅳ级,腹腔镜远端胃切除术组有13例患者(6.3%)发生。病理分期为IB期的患者有109例(36.3%),ⅡA期77例(25.7%),ⅡB期48例(16.0%),ⅢA期31例(10.3%),ⅢB期19例(6.3%),ⅡIC期16例(5.3%)。中位随访期为55.2个月。IB期患者的3年无复发生存(RFS)率为92.7%,ⅡA期为87.0%,ⅡB期为68.8%,ⅢA期为64.5%,ⅢB期为47.4%,ⅡIC期为43.8%。IB期患者的5年实际总生存率为91.1%,Ⅱ期为72.7%,Ⅲ期为62.5%。多因素分析显示术后并发症是RFS的独立危险因素。
AGC的LG是可行的,且肿瘤学结局与先前报道的相当。术后并发症与预后不良相关。应进行随机对照试验以证实LG治疗AGC在普通人群中的这些结果。